FRONTAGE HLDG CP UNSP/ADR - FTHCY STOCK NEWS

Frontage Holdings Corporation appoints Mr. Henry Gao as Chief Financial Officer and President of Asia Pacific. With over 25 years of experience in finance, audit, investment, and project management, Mr. Gao's extensive expertise in leading IPO and M&A projects will play a pivotal role in driving Frontage's continued success.

Frontage Laboratories, Inc. (FRL) has completed the acquisition of the Bioanalytical and Drug Metabolism & Pharmacokinetics businesses of Accelera S.r.l, a premier Contract Research Organization in Italy, marking a significant achievement in establishing a base of operations in continental Europe. The acquisition is intended to benefit both existing Frontage and Accelera clients by leveraging Frontage's global platform and presents opportunities for further expansion in Europe.

Frontage Holdings Corporation (FRNT) appoints Mr. Henry Gao as President of Asia Pacific, leveraging his extensive experience in finance, audit, investment, project management, compliance, and board office. Mr. Gao aims to lead Frontage's Asia Pacific operations to become a premier CRO platform in China and beyond.

Frontage Laboratories, Inc. and its subsidiary, Frontage Canada, Inc., have completed the acquisition of Nucro-Technics Inc. and its affiliate Nucro-Technics Holdings, Inc. Nucro-Technics is a pharmaceutical contract research organization that offers various services including analytical chemistry, microbiology, toxicology, bioanalytical, and stability sample storage and testing services. The acquisition strengthens Frontage's presence in Canada and expands its suite of services globally.

Frontage Holdings Corporation has announced the promotions of Dr. Abdul Mutlib to CEO and Dr. John Lin to President as of January 3, 2023. Dr. Mutlib has over 12 years of experience with Frontage, leading the Preclinical business, while Dr. Lin has been with the company for over 15 years, focusing on Bioanalytical and Biologics services. Founder Dr. Song Li remains Executive Chairman, emphasizing a focus on strategic growth. The leadership changes aim to enhance operational performance and prepare for future expansion, leveraging their extensive industry experience.

Frontage Laboratories announced a collaboration with Eisai and Biogen to support the bioanalysis of lecanemab (BAN2401) in a phase 3 study for Alzheimer's disease.

The study met aggressive timelines, showcasing Frontage's commitment to addressing medical needs. Notably, the study has delivered favorable results as highlighted in a presentation on November 29, 2022.

Frontage's scientific team contributed to biomarker analysis, reinforcing their role in global clinical research.

Frontage Holdings Corporation announced that its Frontage Central Labs has received accreditation from the College of American Pathologists (CAP). The accreditation follows a thorough inspection, highlighting the lab's commitment to quality and compliance with CLIA, FDA, and OSHA standards. This achievement reflects Frontage's dedication to high-quality services and scientific expertise, enhancing patient care and safety. The company provides integrated research, analytical, and development services globally, supporting biopharmaceutical companies in product development.

Frontage Laboratories announces the opening of a new 19,000 square foot laboratory in Hayward, California, designed to enhance support for the biotech and pharmaceutical sectors. The facility offers GLP-compliant Ligand Binding Assay services, pharmacokinetics, immunogenicity, and biomarker analysis for protein therapeutics. Additionally, it will aid in providing quantitative mass spectrometry services targeting preclinical and clinical studies. Dr. Song Li emphasizes the company's commitment to technology and customer service, attributing growth to client partnerships.